Keywords: biologische Marker, D110, Differentialtherapie, Heterogenität, MOG, Multiple Sklerose, Prognose, biological markers, differential therapeutic concept, Heterogeneity, multiple sclerosis, Prognosis
10/2004 | LaboratoriumsMedizin, Walter de Gruyter